Marcus Edelmann

Marcus Edelmann

Auto-generated profile, based on publicly available information

Marcus Edelmann

Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
Treatment of patients with locally advanced rectal cancer (RC) is based on neoadjuvant chemoradiotherapy followed by surgery. In order to reduce the development of therapy resistance, it is necessary to further improve previous treatment approaches. Recent in vivo experimental studies suggested that the reduction of tumor hypoxia by tumor vessel normalization (TVN), through the inhibition of the glycolytic activator PFKFB3, could significantly improve tumor response to therapy. We have evaluated in vitro and in vivo the effects of the PFKFB3 inhibitor 2E-3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) on cell survival, clonogenicity, migration, invasion, and metabolism using colorectal cancer cells, patient-derived tumor organoid (PDO), and xenograft (PDX). 3PO treatment of colorectal cancer cells increased radiation-induced cell death and reduced cancer cell invasion. Moreover, gene set enrichment analysis shows that 3PO is able to alter the metabolic status of PDOs toward oxidative phosphorylation. Additionally, in vivo neoadjuvant treatment with 3PO induced TVN, alleviated tumor hypoxia, and increased tumor necrosis. Our results support PFKFB3 inhibition as a possible future neoadjuvant addition for patients with RC. Significance: Novel therapies to better treat colorectal cancer are necessary to improve patient outcomes. Therefore, in this study, we evaluated the combination of a metabolic inhibitor (3PO) and standard radiotherapy in different experimental settings. We have observed that the addition of 3PO increased radiation effects, ultimately improving tumor cell response to therapy.

28 March 2025
Verified
Other
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
Supplementary Fig.1 from Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon Radiotherapy

28 March 2025
Verified
Other
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
3PO affects normal epithelial and colorectal cancer cell proliferation and viability in a concentration-dependent manner. A, xCELLigence assay performed with HCT-116, HT-29, SW-1463, SW-837, HUVECs, and RPE-1 cells. Real-time cell analysis following treatment with different concentrations of 3PO over a period of 96 hours. Dotted lines indicate the fitted saturation curve in logarithm, n = 3 independent experiments. B and C, CellTiter-Blue assay performed with HCT-116, HT-29, SW-1463, SW-837, HUVECs, and RPE cells treated with different concentrations of 3PO for 24 and 48 hours. D and E, LDH assay performed with HCT-116, HT-29, SW-1463, SW-837, HUVECs, and RPE cells treated with different concentrations of 3PO for 24 and 48 hours. B–E, Data are displayed as means SD, ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001; ∗∗∗∗, P < 0.0001. One-way ANOVA was used to calculate statistical significance, n = 3 independent experiments.

9 August 2024
Verified
Other
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
3PO administration in combination with radiotherapy increases tumor necrosis and DNA damage in RC cells in vivo. A, Relative body weight curves of mice in different therapy groups. B, Relative growth curve of rectal PDX tumors upon treatment with vehicle (control; n = 5), 3PO (25 mg/kg; 3×/week; n = 4), RT (1.8 Gy single dose; 5×/week; n = 4), and dual therapy 3PO + RT (25 mg/kg; 3×/week; 1.8 Gy single dose; 5×/week; n = 5). Arrows indicate administration of 3PO and RT. Data are displayed as means ± SEM, ∗, P < 0.05; one-way ANOVA. ∗, P value refers to RT or RT + 3PO compared with control. C, PDX tumor weight. Data are displayed as means ± SD. ∗, P < 0.05; one-way ANOVA. D, Representative H&E staining images of PDX tumors upon treatment with vehicle (control), 3PO, RT, and 3PO + RT. Scale bars, 500 and 100 µm. Arrow heads: representative necrotic areas; asterisks: viable tumor areas. E, Viable tumor area quantification (% of total tumor area). Data are displayed as means SD. ∗, P < 0.05; ∗∗∗∗, P < 0.0001; Student t test. F, Quantification of apoptosis by cleaved caspase-3 staining. Data are displayed as means SD. ∗∗∗, P < 0.001; ∗∗∗∗, P < 0.0001; one-way ANOVA. G, Quantification of DNA fragmentation using TUNEL staining. Data are displayed as means SD. ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗∗, P < 0.0001; one-way ANOVA. H, Representative images from TUNEL staining in PDX tumors upon treatment with vehicle (control), 3PO, RT, and 3PO + RT. Scale bars, 25 µm. I, Quantification of proliferation using bromodeoxyuridine (BrdU) staining. Data are displayed as means ± SD. ∗, P < 0.05; ∗∗∗∗, P < 0.0001; one-way ANOVA. J, Quantification of PFKFB3 expression in tumor tissue. Data are displayed as means SD. ∗∗∗, P < 0.001; ∗∗∗∗, P < 0.0001; one-way ANOVA. K, Representative images from PFKFB3 staining in PDX tumors upon treatment with vehicle (control), 3PO, RT, and 3PO + RT. Scale bars, 200 µm.

9 August 2024
Verified
Other
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
Supplementary Fig. 7 from Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon Radiotherapy